Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Core Insights - Werewolf Therapeutics, Inc. is set to present three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting its innovative biopharmaceutical developments aimed at stimulating the immune system for cancer treatment [1][2]. Company Overview - Werewolf Therapeutics is focused on developing conditionally activated therapeutics designed to enhance the body's immune response against cancer and other immune-mediated conditions [3]. - The company utilizes its proprietary PREDATOR platform to create INDUKINE™ and INDUCER™ molecules that selectively activate in the tumor microenvironment while remaining inactive in peripheral tissues [3]. - The lead clinical candidates include WTX-124 and WTX-330, which are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) molecules, respectively, aimed at treating solid tumors [3]. Upcoming Presentations - The first poster will discuss the sequential administration of WTX-124 and mWTX-330, demonstrating enhanced antitumor activity in mice with poorly immunogenic EMT6 tumors without systemic toxicity [2]. - The second poster will focus on the development of conditional T cell engagers (INDUCER™ molecules) that utilize a masking approach to minimize dose-limiting cytokine release and off-target toxicity [2]. - The third poster will provide pharmacokinetic insights into the IL-2 INDUKINE prodrug WTX-124, assessing tumor-specific activation and immune modulation in real-time [2].